Oncology innovation is accelerating, but the ability to turn congress interactions into timely, actionable insights remains a challenge. High volumes of unstructured MSL and HCP data often slow analysis, limit visibility and delay strategic action.
This challenge is the focus of the second installment in our ongoing thought leadership series. Building on the first paper, it explores how a Congress Intelligence Agent can transform raw interaction data into structured, data-driven insights to help teams reduce bias, accelerate decision-making, and better understand evolving market needs.
This is the next step in rethinking oncology commercialization. Download the white paper to see how organizations can turn congress dialogue into a strategic advantage.
Author
Tim has served as a strategic lead to healthcare companies for more than 25 years in advertising, marketing, and finance roles in agency and client settings. His work spans pre-clinical to sunset strategies and from brand infrastructure to digital roadmaps. He has helped stand up clinical trial…
Nick brings 20+ years of experience in strategic brand building and stewardship in pharma to EVERSANA INTOUCH...
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…